Br exit, execs selling stock, these are the sorts of risks management has exposed us to.
And many others...!! By getting out of bed in the morning, you're exposed to risks.
The ones you mention are minimal risks, in the overall scheme of things. The safe thing is to sell Ariad pronto, but then, you "accept" the risk of not making the profit that Ariad's current progress points to.
BTW, the effect of Brexit is pretty small, and in the long term insignificant. Ditto for "execs selling stock" (which in this instance was set in motion years ago).
The important thing to remember (with respect to Ariad) is that:
1. we have top notch people in charge (and the fact that they're not taking advice from posters on this board increases my respect for them).
2. the progress in getting recognition for Ariad's products as very valuable tools in the armamentarium against multiple cancers, with unique efficacy in reducing mutations,
3. and contrary to your often repeated concerns about Ariad's finances, we are in fact in extremely good shape to execute as planned (with or without a near term BO).
Risks come and go! With Ariad's Eu. deal, the money issue has been settled. Nobody expected this to happen, and voila..., out of the blue a deal.
I'm looking forward to more skillful risk management from PP and Denner and a convergence of Ariad's inherent value and the pps.
Market Data 
Markets 
AI
